NASDAQ: LFCR
Lifecore Biomedical Inc Stock

$4.75+0.00 (+0%)
Updated Jul 10, 2026
LFCR Price
$4.75
Fair Value Price
$9.08
Market Cap
$178.17M
52 Week Low
$3.63
52 Week High
$8.98
P/E
N/A
P/B
-6.27x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-7.2
Operating Cash Flow
N/A
Beta
1.11
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

LFCR Overview

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine LFCR's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
B
LFCR
Ranked
#36 of 53

Top Ranked Stocks in Industry

View Top Pharmaceutical Stocks

Be the first to know about important LFCR news, forecast changes, insider trades & much more!

LFCR News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LFCR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LFCR ($4.75) is undervalued by 47.69% relative to our estimate of its Fair Value price of $9.08 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
LFCR ($4.75) is significantly undervalued by 47.69% relative to our estimate of its Fair Value price of $9.08 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
LFCR's short-term assets ($77.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more LFCR due diligence checks available for Premium users.

Valuation

LFCR fair value

Fair Value of LFCR stock based on Discounted Cash Flow (DCF)

Price
$4.75
Fair Value
$9.08
Undervalued by
47.69%
LFCR ($4.75) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LFCR ($4.75) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

LFCR price to earnings (PE)

For valuing profitable companies with steady earnings

Company
0x
Industry
-5.88x
Market
12.99x

LFCR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-6.27x
Industry
1.56x

LFCR's financial health

Profit margin

Revenue
$23.2M
Net Income
-$15.0M
Profit Margin
-68.7%

Assets to liabilities

Assets
$225.5M
Liabilities
$204.7M
Debt to equity
-7.2
LFCR's short-term assets ($77.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LFCR's long-term liabilities ($184.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LFCR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LFCR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$4.7M
Investing
-$1.1M
Financing
-$256.0k

LFCR vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
LFCRC$178.17M0.00%N/A-6.27x
DERMB$190.26M-1.29%-18.68x6.17x
ACBF$159.75M+0.37%-1.75x0.43x
OGID$131.97M-1.43%-6.40x0.48x
CRDLD$112.99M+1.81%-3.52x6.35x

Lifecore Biomedical Stock FAQ

What is Lifecore Biomedical's quote symbol?

(NASDAQ: LFCR) Lifecore Biomedical trades on the NASDAQ under the ticker symbol LFCR. Lifecore Biomedical stock quotes can also be displayed as NASDAQ: LFCR.

If you're new to stock investing, here's how to buy Lifecore Biomedical stock.

What is the 52 week high and low for Lifecore Biomedical (NASDAQ: LFCR)?

(NASDAQ: LFCR) Lifecore Biomedical's 52-week high was $8.98, and its 52-week low was $3.63. It is currently -47.1% from its 52-week high and 31.03% from its 52-week low.

How much is Lifecore Biomedical stock worth today?

(NASDAQ: LFCR) Lifecore Biomedical currently has 37,509,407 outstanding shares. With Lifecore Biomedical stock trading at $4.75 per share, the total value of Lifecore Biomedical stock (market capitalization) is $178.17M.

Lifecore Biomedical stock was originally listed at a price of $3.50 in Dec 31, 1997. If you had invested in Lifecore Biomedical stock at $3.50, your return over the last 28 years would have been 35.71%, for an annualized return of 1.1% (not including any dividends or dividend reinvestments).

How much is Lifecore Biomedical's stock price per share?

(NASDAQ: LFCR) Lifecore Biomedical stock price per share is $4.75 today (as of Jul 10, 2026).

What is Lifecore Biomedical's Market Cap?

(NASDAQ: LFCR) Lifecore Biomedical's market cap is $178.17M, as of Jul 13, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Lifecore Biomedical's market cap is calculated by multiplying LFCR's current stock price of $4.75 by LFCR's total outstanding shares of 37,509,407.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.